Last 12 months
Inside the activity.
1 purchase rows · 32 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 8 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 14 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2017 Filed Oct 5, 2017 23:50 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
GrantOption (right to buy) · Derivative | 110,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000170 · wf-form4_150724738946208.xml · derivative · entry 3 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2024-10-02 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:50 UTC |
Lamb PeterEVP, Scientific Strategy & CSO
|
GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000170 · wf-form4_150724738946208.xml · nonDerivative · entry 1 Lamb Peter · CIK 0001387306 · EVP, Scientific Strategy & CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,600 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 71,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:49 UTC |
Hessekiel JeffreyEVP and General Counsel
|
GrantOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000169 · wf-form4_150724734336550.xml · derivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2024-10-02 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:49 UTC |
Hessekiel JeffreyEVP and General Counsel
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000169 · wf-form4_150724734336550.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,946 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 66,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:48 UTC |
Senner Christopher J.EVP and CFO
|
GrantOption (right to buy) · Derivative | 125,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000168 · wf-form4_150724728309076.xml · derivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2024-10-02 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:48 UTC |
Senner Christopher J.EVP and CFO
|
GrantCommon Stock | 62,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000168 · wf-form4_150724728309076.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,259 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested F3 · balance_after: Includes 82,500 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:47 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantOption (right to buy) · Derivative | 480,000 | $0.00 Strike: $24.41 | $0.00 |
DisclosureSEC source: 0000939767-17-000167 · wf-form4_150724722891461.xml · derivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2024-10-02 F6 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. Option granted will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 23:47 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000167 · wf-form4_150724722891461.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on November 15, 2018, and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each November 15th until fully-vested. F3 · balance_after: Includes 140,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · derivative · entry 7 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,698 Underlying: Common Stock · 25,000 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
SaleCommon Stock | 25,000 | $24.32 | $608,000.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 4 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,946 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.20 to $24.40. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionCommon Stock | 25,000 | $1.90 | $47,500.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 3 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,946 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 33,334 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 10 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,334 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 33,334 | $23.74 | $791,349.16 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 6 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.70 to $23.76. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4. Read SEC document |
| September 28, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 33,334 | $9.91 | $330,339.94 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 5 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionOption (right to buy) · Derivative | 2,302 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · derivative · entry 6 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,698 Underlying: Common Stock · 2,302 shares Expires 2022-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
SaleCommon Stock | 2,302 | $23.90 | $55,017.80 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 2 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,946 Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:47 UTC |
Hessekiel JeffreyEVP and General Counsel
|
Exercise / conversionCommon Stock | 2,302 | $1.90 | $4,373.80 |
DisclosureSEC source: 0000939767-17-000160 · wf-form4_150664245733663.xml · nonDerivative · entry 1 Hessekiel Jeffrey · CIK 0001599803 · EVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,248 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,250 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 9 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Stock · 33,333 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 33,333 | $23.94 | $797,992.02 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 4 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.70 to $24.22. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| September 27, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 33,333 | $9.91 | $330,330.03 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 3 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionOption (right to buy) · Derivative | 33,333 | $0.00 Strike: $9.91 | $0.00 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · derivative · entry 8 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,667 Underlying: Common Stock · 33,333 shares Expires 2017-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option, representing the right to purchase a total of 200,000 shares of Exelixis, Inc. common stock, became fully exercisable on December 6, 2011. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
SaleCommon Stock | 33,333 | $23.68 | $789,325.44 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 2 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,005 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.66 to $23.80. Reporting person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 23:45 UTC |
Schwab GiselaPres Prod Dev & Med Aff & CMO
|
Exercise / conversionCommon Stock | 33,333 | $9.91 | $330,330.03 |
DisclosureSEC source: 0000939767-17-000159 · wf-form4_150664232692666.xml · nonDerivative · entry 1 Schwab Gisela · CIK 0001213140 · Pres Prod Dev & Med Aff & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,338 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 22, 2017 Filed Sep 22, 2017 23:07 UTC |
PAPADOPOULOS STELIOSDirector
|
SaleCommon Stock | 10,000 | $25.40 | $254,000.00 |
DisclosureSEC source: 0000939767-17-000155 · wf-form4_150612161860966.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · shares: Shares were held by Fondation Sante, of which the Reporting Person is co-trustee. Read SEC document |
| September 19, 2017 Filed Sep 20, 2017 22:48 UTC |
PAPADOPOULOS STELIOSDirector
|
SaleCommon Stock | 127,790 | $27.63 | $3,530,837.70 |
DisclosureSEC source: 0000939767-17-000153 · wf-form4_150594771411919.xml · nonDerivative · entry 2 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,034,314 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.60 to $27.73. Reporting Person undertakes to provide Exelixis, Inc., any security holder ofExelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to thisForm 4 Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 22:48 UTC |
PAPADOPOULOS STELIOSDirector
|
SaleCommon Stock | 72,210 | $27.76 | $2,004,549.60 |
DisclosureSEC source: 0000939767-17-000153 · wf-form4_150594771411919.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,162,104 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.74 to $27.78. Reporting Person undertakes to provide Exelixis, Inc., any security holder ofExelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to thisForm 4 F2 · balance_after: Includes 5,843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · derivative · entry 11 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 804,551 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 100,000 | $27.08 | $2,708,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 6 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F4 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.97 to $27.20. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4 Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 5 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 14, 2017 Filed Sep 15, 2017 22:43 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 60,640 | $27.21 | $1,650,014.40 |
DisclosureSEC source: 0000939767-17-000151 · wf-form4_150551540227057.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,553 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $27.19 to $27.25. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4. F2 · balance_after: Includes 27,553 shares of Exelixis, Inc common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 2,361 shares of common stock acquired pursuant to the Exelixis , Inc. 2000 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:18 UTC |
WILLSEY LANCEDirector
|
SaleCommon Stock | 50,000 | $26.97 | $1,348,500.00 |
DisclosureSEC source: 0000939767-17-000149 · wf-form4_150543109685590.xml · nonDerivative · entry 2 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,273 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.81 to $27.29. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4 Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · derivative · entry 10 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 904,551 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 100,000 | $27.04 | $2,704,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 4 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.90 to $27.35. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4 Read SEC document |
| September 13, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 3 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:18 UTC |
WILLSEY LANCEDirector
|
SaleCommon Stock | 50,000 | $26.79 | $1,339,500.00 |
DisclosureSEC source: 0000939767-17-000149 · wf-form4_150543109685590.xml · nonDerivative · entry 1 WILLSEY LANCE · CIK 0001202106 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,273 F1 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.59 to $26.94. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 1 to this Form 4 Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:17 UTC |
Senner Christopher J.EVP and CFO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-17-000148 · wf-form4_150543102162859.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 100,000 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, was exercisable as to 182,291 shares on the Transaction Date. Th remainder of the option will vest as to 1/48th of the original number of shares subject to the option on each monthly anniversary of July 15, 2015 grant date. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:17 UTC |
Senner Christopher J.EVP and CFO
|
SaleCommon Stock | 100,000 | $26.79 | $2,679,000.00 |
DisclosureSEC source: 0000939767-17-000148 · wf-form4_150543102162859.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,759 Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:17 UTC |
Senner Christopher J.EVP and CFO
|
Exercise / conversionCommon Stock | 100,000 | $3.66 | $366,000.00 |
DisclosureSEC source: 0000939767-17-000148 · wf-form4_150543102162859.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 20,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 2,361 shares of common stock acquired pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionOption (right to buy) · Derivative | 100,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · derivative · entry 9 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,004,551 Underlying: Common Stock · 100,000 shares Expires 2021-09-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option, representing the right to purchase a total of 1,125,000 shares of Exelixis, Inc. common stock, became exercisable as to fifty percent (50%) of the shares subject to the option on July 20, 2015, as to twenty-five (25%) of the shares subject to the option on March 7, 2016 and as to the remaining twenty-five (25%) of the shares subject to the option on April 28, 2016. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
SaleCommon Stock | 100,000 | $26.59 | $2,659,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 2 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.44 to $26.70. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4 Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 23:14 UTC |
MORRISSEY MICHAELDirector · President and CEO
|
Exercise / conversionCommon Stock | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000939767-17-000147 · wf-form4_150543088058214.xml · nonDerivative · entry 1 MORRISSEY MICHAEL · CIK 0001202096 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 60,000 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 23:09 UTC |
Haley Patrick J.Sr. Vice President, Commercial
|
SaleCommon Stock | 5,000 | $18.46 | $92,300.00 |
DisclosureSEC source: 0000939767-17-000122 · wf-form4_149635852953858.xml · nonDerivative · entry 1 Haley Patrick J. · CIK 0001692954 · Sr. Vice President, Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,193 F1 · balance_after: Includes 27,553 shares of Exelixis, Inc common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:53 UTC |
Smith JulieDirector
|
GrantOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000117 · wf-form4_149584640178321.xml · derivative · entry 1 Smith Julie · CIK 0001557928 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC |
SCANGOS GEORGE ADirector
|
GrantOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000116 · wf-form4_149584634971456.xml · derivative · entry 1 SCANGOS GEORGE A · CIK 0001202102 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC |
POSTE GEORGEDirector
|
GrantOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000115 · wf-form4_149584630514283.xml · derivative · entry 2 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,686 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:52 UTC |
POSTE GEORGEDirector
|
GrantCommon Stock | 5,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000115 · wf-form4_149584630514283.xml · nonDerivative · entry 1 POSTE GEORGE · CIK 0001180770 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,398 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the sharessubject to the restricted stock unit award on May 25, 2018, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 5.843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:51 UTC |
FELDBAUM CARL BDirector
|
GrantOption (right to buy) · Derivative | 23,491 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000114 · wf-form4_149584625322744.xml · derivative · entry 1 FELDBAUM CARL B · CIK 0001326377 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,491 Underlying: Common Stock · 23,491 shares Expires 2024-05-24 F1 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:49 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000112 · wf-form4_149584614868140.xml · derivative · entry 2 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,686 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:49 UTC |
PAPADOPOULOS STELIOSDirector
|
GrantCommon Stock | 5,843 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-17-000112 · wf-form4_149584614868140.xml · nonDerivative · entry 1 PAPADOPOULOS STELIOS · CIK 0001202098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,314 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 100% of the sharessubject to the restricted stock unit award on May 25, 2018, subject to the Reporting Person's continuous service through such date. F3 · balance_after: Includes 5.843 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| May 25, 2017 Filed May 27, 2017 00:50 UTC |
WYSZOMIERSKI JACK LDirector
|
GrantOption (right to buy) · Derivative | 11,686 | $0.00 Strike: $19.57 | $0.00 |
DisclosureSEC source: 0000939767-17-000113 · wf-form4_149584620186199.xml · derivative · entry 2 WYSZOMIERSKI JACK L · CIK 0001023225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,686 Underlying: Common Stock · 11,686 shares Expires 2024-05-24 F4 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/12th of the shares subject to the option each month following the date of grant, subject to the Reporting Person's continuous service through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.